Quote this publication Share Print

PROCORALAN

-
Opinions on drugs - Posted on May 29 2006

Reason for request

Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals

-


Clinical Benefit

Substantial

The actual medical benefit of this proprietary drug in this indication is significant.


Clinical Added Value

moderate

The Transparency Committee considers that PROCORALAN provides a moderate improvement in actual benefit (IAB III) in patients with chronic stable angina with a contraindication or intolerance to beta-blockers and with asymptomatic left ventricular dysfunction (LVEF < 45 %) contraindicating the use of heart rate-decreasing calcium antagonists.


Contact Us

Évaluation des médicaments